Article Sidebar

Submitted
9 January 2021
Accepted
9 January 2021
Published
31 March 2019
Download
PDF
Statistic
Read Counter : 532 Download : 669

Main Article Content

Abstract

Thrombocytopenia is a common abnormality in patients presenting with acute coronary syndrome. Baseline thrombocytopenia in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention is associated with early adverse events, related to both ischemia and bleeding. Treatment for acute coronary syndrome usually involves antiplatelet, anticoagulant, antithrombotic therapy, and the performance of percutaneous coronary intervention. The safety of antiplatelet therapy and percutaneous coronary intervention patients who have acute coronary syndrome and thrombocytopenia is unknown, and there are no guidelines or randomized studies that specifically suggest a treatment approach in such patients. One of the institutions in Italy recommends medical and interventional strategy with radialis as first choice for access site, bare metal stent (BMS) implantation, followed by double antiplatelet therapy (DAPT) for one month. After DAPT discontinuation, at least one antiplatelet drug (aspirin) is recommended for life.

Keywords

Thrombocytopenia percutaneous coronoray intervention acute coronary syndrome

Article Details

License

Copyright (c) 2019 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Oktaviono, Y. H., & Meuthia, F. (2019). Thrombocytopenia in a Patient Undergoing Primary Percutaneous Coronary Intervention. Folia Medica Indonesiana, 55(1), 68–73. https://doi.org/10.20473/fmi.v55i1.24434
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Campo G, Marchesini J, Fileti L, Tebaldi M, Ferrari R. 2012. Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. J Thromb Haemost 10:153-6.
  2. Darcy MD, Kanterman RY, Kleinhoffer MA, Vesely TM, et al. 1996. Evaluation of coagulation tests as predictors of angiographic bleeding complications. Radiology 198:741-4.
  3. Goldberg GL, Gibbon DG, Smith HO, DeVictoria C, et al. 1994. Clinical impact of chemotherapy induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 12:2317-20.
  4. Hakim DA, Dangas GD, Caixeta A, Nikolsky E, et al. 2011. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J 161:391-6.
  5. Hayashi H, Beppu T, Shirabe K, Maehara Y, Hideo B. 2014. Management of thrombocytopenia due to liver cirrhosis: A review. World J Gastroenterol 20:2595-2605.
  6. Keeley EC, Boura JA, Grines CL. 2003. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13-20.
  7. Levine GN, Bates ER, Blankenship JC, Bailey SR. 2011. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC 58:e44-122.
  8. Levine GN, Bates ER, Bitti JA, Brindis RG, et al. 2016. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. JACC.
  9. Makris M, Veen JJ, Tait AD, Mumford AD, et al. 2012. Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology 160:35-46.
  10. O'Gara PT, Kushner FG, Ascheim DD, Jr DEC, Chung MK. 2013. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the
  11. American College of Cardiology Foundation/American American Heart Association Task Force on Practice Guidelines. Circulation 127:362-425.
  12. Overgaard CB, Ivanov J, Seidelin PH, Todorov M, et al. Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J 156:120-4.
  13. Sarkiss MG, Yusuf SW, Warneke CL, Botz G, et al. 2007. Impact of Aspirin Therapy in Cancer Patients With Thrombocytopenia and Acute Coronary Syndromes. Cancer 109:621-7.
  14. Spoon DB, Psaltis PJ, Kidd S, Prasar A, et al. 2013. Outcomes after PCI in patients with thrombocytopenia. JACC 61:e1718.
  15. Tosetto A, Balduini CL, Cattaneo M, DeCandia E, et al. 2009. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis research 124:e13-18.
  16. Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. 2010. Antiplatelet Therapy and Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome and Thrombocytopenia. Tex Heart Inst J 37:336-40.